The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@ Rowka very very glad to see you back. Sorry to hear about your difficult childhood and glad things came good for you.
I found all your posts informative, balanced and well written. I hope to read more but well understand if you no longer have the time. I will also donate to your children's home when the time comes.
These BBs are full of ghastly and uninformed people whose own inadequacies are all too transparent. I wish LSE had an easy to use delete function. You have been very patient in dealing with those people. I haven't got that patience so seldom post. The very best of luck to you and your family.
R
@ Ian_
Please put me down for 28th August 2020 for the next meaningful RNS.
Final share price 78p based on accepted offer of 2Bn GBP. Obviously I hope it will be a lot more.
Many thanks for organising and making this BB a bit of light hearted fun. Much appreciated in these difficult and uncertain times.
GLA
R
@ Vegas22
Copied and pasted from the RNS:
"I am delighted that the COVID-19 BAMS assay that we are developing with Adeptrix has been accepted into the CONDOR programme. This provides us with access to patient samples and partners in UK hospitals to rapidly carry out the validation studies that are critical to progress the BAMS assay development.......
.........I am also very pleased that the CONDOR programme will support the clinical validation of the rapid saliva-based COVID-19 antigen test strip that we are developing with Cytiva. This, combined with other collaborations that we are putting in place, will provide us with access to a sufficient number of COVID-19 patient samples to allow us to quickly clinically validate the saliva rapid test.
Vegas why do you think Dr Smith makes these comments about "access to samples" if this hasn't been a problem outside of CONDOR?
Often RNS announcements contain coded messages. If AVacta has been held back because it hasn't been able to source an adequate range of samples this could be considered political dynamite. So Dr Smith has had to turn a negative into a positive by saying joining CONDOR has significantly helped AVacta. He could have said, this useless government has finally woken up to the fact real-time Antigen tests are the only way to test track and trace and let AVacta join CONDOR, but he is clearly up for an Honour when he delivers on his promises!
DYOR GLA
R
I seldom post because of the moronic responses but did anyone else here read the RNS of 22nd July and form the view that AVacta has had difficulty obtaining Covid-19 saliva samples? Dr Smith mentions three times in the RNS that joining the CONDOR programme gives AVacta much better access to samples. The inference I drew was that previously obtaining samples had been an issue and caused delay.
There have also been BB discussions on Biosecurity of the LFT PoC test. This applies to all COVID-19 tests/samples (and tests for similar airborne contagious viruses I suspect ). Does anyone know what the procedures are for the current range of tests/samples and if any Biosecurity measures are currently in place?
My personal view is that if Biosecurity can be easily achieved with the addition of a neutralising agent then that's excellent, but the need for real-time Antigen tests is now so desperate that Biosecurity could be achieved through adequate instructions and an included disposal bag. At least in the short-term.
News always takes longer than expected, and the wait is obviously excruciating for those holders who are over-extended or gambling money they don't have or can't afford to lose. GLA.
I'm beginning to think the Boots tie-up is now the wrong move as like all bricks and mortar shops it's facing significant challenges due to Covid.
Mothercare is a very strong brand name. The business is headless and has gone into hiding. The last RNS talks about trivia.
A much better match would be with BooHoo. Both internet retailers, MTC has significant worldwide presence.
BOO is acquiring brands and has drive and enthusiasm but needs to widen its fashion offerings as the 20s somethings start a family. Better range of baby, toddlers, childrens and maternity clothes. Could be highly profitable with a brand name everyone trusts. Also could be good PR for Boo.
MTC probably isn't in play until November but food for thought?
30,000 shares here not impatient but bored...
GLA DYOR
R
@chrisengland If you want to be in airlines look at WIZZ. Doesn't have the same baggage problems as IAG and EZJ. (Pun intended.) Travel recovery too early for me and not sure CCL will survive in its current form.
My buy button is taped up at the moment apart from three or four speculative AIM stocks and here.
GLA
R
@Elkarter & galpat I agree markets are in for a short term tumble. End of July into August has seen a dip last few years. Fund managers are on holiday and leave inexperienced colleagues in charge. They will panic and sell at the first sign of a dip. Friday may have been the start. I'm 95% in cash until September and then will review. 2nd wave, US election, US/China Brexit and liquidity and debt make me bearish.
I'm highly selective at the moment but BooHoo I think will weather the storm better than most.
GLA
R
Comparative Newbie to EUA post suspension. Very well done LTHs.
The only similar situation I was involved in was Dee Valley water acquired by Severn Trent Water. From memory a Hedge Fun made a competing bid after the BoD had accepted Severn's offer. Caused some issues but increased the eventual sale price. I also recall there were regulatory issues.
Can anyone confirm whether there would be any Regulatory or Monopoly concerns associated with any bidders?
Many thanks and GLA
R
BoJo said the governments want to ramp up to 500,000 ANTIGEN tests a day - 3.5 million a week. (Assumes 7 day testing!)
He then went on to say that test and trace needed to detect at a local level in REALTIME. Instantaneous Detection to achieve Fast Containment. Test Track and Trace has much improved and he believes by Oct/Nov the gov will achieve its goal of realtime Antigen testing.
Dido effectively rubbished Antibody testing as not helping identify outbreaks, only telling you if you have antibodies or not, and the science doesn't yet know whether antibodies give protection or not.
In my view it couldn't be clearer that they both are looking for an Avacta type solution for realtime testing. I believe they wouldn't have said this unless they believe such a test can be delivered.
I'm doubling my stake here on the back of what I heard.
DYOR GLA
R
@Jon
Any thoughts about the continuing radio silence? I noted with thanks your post about the administrator sharing any sale proceeds before November which may suggest the BoD isn't in any hurry to do anything? I guess time will tell, and compared to other shares I'm invested in, this board is delightfully quiet!
GLA
R
The government is working in the dark because we do not have a widely available rapid easy to use Point of Care Test. If/when Avacta/Cytiva can prove their test works this is going to be very big news. Therefore the timing of the news may be being influenced by external factors. Food for thought?
GLA
R
The last time the closing price was significantly manipulated down at close was followed by a 7.00 am RNS announcing the £45m Rights Issue. As another RI can't be on the cards, what is the reason? Possible bid to be announced tomorrow or just silly MM games?
I haven't received my allocation either. I use Jarvis as it is linked to this site.
I am slightly surprised not to have received the shares. I can understand why they can't put them into an ISA. I had to open a nominee account just to receive them, but will sell at some point as my ISA is maxed out for this year.
@Ophidian It's our investment and I wish you and everyone else the best of luck with it.
I'm looking forward to the RNS which confirms the test meets Avacta's and Cytiva's criteria for success just like everyone else.
In the meantime I worry.
GLA
R
@ Ophidian
Firstly I have the greatest respect for you and your posts. You clearly have a wealth of knowledge regarding this technology which I do not have. you are also prepared to share this with everyone on here.
My orginal post suggested that you can read the RNS two ways. You appear to have opted for 1. That's fine and very good to hear.
GLA
R
O&W not quite true on IMM. The CEO had warned that Lupuzor might not achieve statistically better results that a placebo and SoC and we all ignored him.
AS nor anyone else has yet stated the test works. The trouble is we often read what we want to see. I have £20K invested that this will work, but I was over committed and took this RNS as a reason to take profits.
I'm 90% sure this will work out well, but I was 100% before 07.03 today.